Immunoadsorption in patients with chronic inflammatory demyelinating polyradiculoneuropathy with unsatisfactory response to first-line treatment

European Neurology

Volumn 66, Issue 4, 2011, Pages 183-189

  Galldiks, Norbert ^a   Burghaus, Lothar ^a   Dohmen, Christian ^a   Teschner, Sven ^a   Pollok, Manfred ^a   Leebmann, Josef ^c   Frischmuth, Nikolaus ^d   Hollinger, Peter ^e   Nazli, Nahed ^e   Fassbender, Cordula ^b   Klingel, Reinhard ^b   Benzing, Thomas ^a   Fink, Gereon R ^a   Haupt, Walter F ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Apheresis Research Institute   (Germany)

^c Department of Internal Medicine   (Germany)

^d Center for Nephrology Marienpark   (Germany)

^e Center for Nephrology   (Germany)

Author keywords

Immunomodulatory treatment; INCAT score; Intravenous immunoglobulin; Tryptophan immunoadsorption

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; PREDNISOLONE; TRYPTOPHAN DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; IMMUNOADSORPTION; MALE; OUTCOME ASSESSMENT; PLASMAPHERESIS; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOSORBENT TECHNIQUES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRYPTOPHAN;

EID: 80052590392     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000331011     Document Type: Article

References (45)

1. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV: Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975;50:621-637.
2. Austin JH: Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 1958;81:157-192.
3. Guillain G, Barré J, Strohl A: Sur un syndrome de radiculonévrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire. Remarques sur les caractères cliniques es graphiques des réflexes tendineux. Bull Soc Med Hop Paris 1916;40:1462-1470.
4. Köller H, Kieseier BC, Jander S, Hartung HP: Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352:1343-1356.
5. Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force: Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) Neurology 1991;41:617-618.
6. Saperstein DS, Katz JS, Amato AA, Barohn RJ: Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311-324. (Pubitemid 32172706)
7. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201. (Pubitemid 32738144)
8. Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK: Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999;66:677-680. (Pubitemid 29186982)
9. Iijima M, Koike H, Hattori N, Tamakoshi A, Katsuno M, Tanaka F, Yamamoto M, Arimura K, Sobue G: Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J Neurol Neurosurg Psychiatry 2008;79:1040-1043.
10. Laughlin RS, Dyck PJ, Melton LJ, 3rd, Leibson C, Ransom J: Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 2009;73:39-45.
11. Hughes RA, Allen D, Makowska A, Gregson NA: Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2006;11:30-46. (Pubitemid 43344973)
12. Yan WX, Taylor J, Andrias-Kauba S, Pollard JD: Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 2000;47:765-775. (Pubitemid 30390197)
13. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA: Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136-144.
14. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996;119:1055-1066. (Pubitemid 26300708)
15. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, Swanson C: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461-465. (Pubitemid 16161945)
16. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-845. (Pubitemid 24370922)
17. van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, Faber CG, van Oostrom JC, Vogels OJ, Hadden RD, Kleine BU, van Norden AG, Verschuuren JJ, Dijkgraaf MG, Vermeulen M: Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:245-253.
18. Van den Bergh PY, Hadden RD, Bouche P, Cornblath DR, Hahn A, Illa I, Koski CL, Leger JM, Nobile-Orazio E, Pollard J, Sommer C, van Doorn PA, van Schaik IN: European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol 2010;17:356-363.
19. Kuitwaard K, van Doorn PA: Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy. Drugs 2009;69:987-1001.
20. Diener H, Putzki N: Leitlinien der Deutschen Gesellschaft für Neurologie, 4. überarb. Aufl. Stuttgart, Thieme, 2008.
21. Choudhary PP, Hughes RA: Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QJM 1995;88:493-502.
22. Isose S, Mori M, Misawa S, Shibuya K, Kuwabara S: Long-term regular plasmapheresis as a maintenance treatment for chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2010;15:147-149.
23. Galldiks N, Dohmen C, Neveling M, Fink GR, Haupt WF: Selective Immune Adsorption Treatment of Severe Guillain Barre Syndrome in the Intensive Care Unit. Neurocrit Care 2009;11:317-321.
24. Seta T, Nagayama H, Katsura K, Hamamoto M, Araki T, Yokochi M, Utsumi K, Katayama Y: Factors influencing outcome in Guillain-Barre Syndrome: comparison of plasma adsorption against other treatments. Clin Neurol Neurosurg 2005;107:491-496. (Pubitemid 41395225)
25. Haupt WF, Rosenow F, van der Ven C, Borberg H, Pawlik G: Sequential treatment of Guillain-Barre syndrome with extracorporeal elimination and intravenous immunoglobulin. J Neurol Sci 1996;137:145-149.
26. Jimenez C, Rosenow F, Grieb P, Haupt WF, Borberg H: Adsorption therapy with tryptophan-conjugated polyvinyl alcohol gels in 10 patients with acute Guillain-Barre syndrome. Transfus Sci 1993;14:9-11. (Pubitemid 23058352)
27. Grob D, Simpson D, Mitsumoto H, Hoch B, Mokhtarian F, Bender A, Greenberg M, Koo A, Nakayama S: Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995;45:338-344.
28. Wagner S, Janzen RW, Mohs C, Pohlmann S, Klingel R, Grutzmacher PW: Long-term treatment of refractory myasthenia gravis with immunoadsorption. Dtsch Med Wochenschr 2008;133:2377-2382.
29. Bucka C, Köhler W, Hertel G, Voigt W, Benn hold I, Schimrigk S, Lange R: Immunoadsorption in myasthenia gravis. Mechanism of action, immunological markers and clinical course (in German). Akt Neurol 1993;20:207-213. (Pubitemid 24019092)
30. Stegmayr BG, Almroth G, Berlin G, Fehrman I, Kurkus J, Norda R, Olander R, Ster ner G, Thysell H, Wikstrom B, Wiren JE: Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study. Int J Artif Organs 1999;22:81-87. (Pubitemid 29158995)
31. Klingel R, Heibges A, Fassbender C: Plasma exchange and immunoadsorption for autoimmune neurologic diseases - current guidelines and future perspectives. Atheroscler Suppl 2009;10:129-132.
32. Hirata N, Kuriyama T, Yamawaki N: Immusorba TR and PH. Ther Apher Dial 2003;7:85-90. (Pubitemid 36648049)
33. Tagawa Y, Yuki N, Hirata K: Ability to remove immunoglobulins and anti-ganglioside antibodies by plasma exchange, double-filtration plasmapheresis and immunoadsorption. J Neurol Sci 1998;157:90-95. (Pubitemid 28179541)
34. Van den Bergh PY, Pieret F: Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2004;29:565-574.
35. Rajabally YA, Nicolas G, Pieret F, Bouche P, Van den Bergh PY: Validity of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy: a multicentre European study. J Neurol Neurosurg Psychiatry 2009;80:1364-1368.
36. Hughes R: Advances in the use of IVIg in neurological disorders. J Neurol 2008;255(suppl 3):1-2.
37. Kresse S, Marx M, Hollinger R, Marx C, Fassbender C, Osten B, Klingel R: Long-term intermittent immunoadsorption (IA) - safe and effective outpatient treatment for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Kidney Blood Press 2000;23:214-347.
38. Ullrich H, Mansouri-Taleghani B, Lackner KJ, Schalke B, Bogdahn U, Schmitz G: Chronic inflammatory demyelinating polyradiculoneuropathy: superiority of protein A immunoadsorption over plasma exchange treatment. Transfus Sci 1998;19(suppl):33-38.
39. Hadden RD, Bensa S, Lunn MP, Hughes RA: Immunoadsorption inferior to plasma exchange in a patient with chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2002;72:644-646. (Pubitemid 34462822)
40. Matsugami K, Endo M, Kimata N, Watanabe Y, Oonuki T, Ando M, Nakazato S, Kubo K, Hihei H, Agishi T: Clinical evaluation of immunoadsorbance in a patient with chronic inflammatory demyelinating polyradiculoneuropathy. Jpn J Apheresis 1994;13:160-161.
41. Zinman LH, Sutton D, Ng E, Nwe P, Ngo M, Bril V: A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy. Transfus Apher Sci 2005;33:317-324. (Pubitemid 41586199)
42. Kribben A, Lütges P, Müller H: Cost-calculation for dialysis and other therapies in nephrology (in German). Krankenhaus 2004;5:356-363.
43. Rote Liste: German official medicines compendium. http://www.rote-liste. de, 2010.
44. Trikha I, Singh S, Goyal V, Shukla G, Bhasin R, Behari M: Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial. J Neurol 2007;254:989-995. (Pubitemid 47353400)
45. Schröder A, Linker RA, Gold R: Plasmapheresis for neurological disorders. Expert Rev Neurother 2009;9:1331-1339.